Selective Inhibition of Na_V1.8 with VX-548 for Acute Pain

Area of Science:

• Pain Management
• Clinical Pharmacology
• Neuroscience

Background:

• The Na_V1.8 sodium channel is crucial for transmitting pain signals in peripheral neurons.
• VX-548 is an oral, selective inhibitor targeting Na_V1.8.

Purpose of the Study:

• To evaluate the efficacy and safety of VX-548 in managing acute pain after surgical procedures.
• To compare different doses of VX-548 against placebo and hydrocodone bitartrate-acetaminophen.

Main Methods:

• Two Phase 2 randomized trials (abdominoplasty and bunionectomy) were conducted.
• Participants received varying doses of VX-548, hydrocodone bitartrate-acetaminophen, or placebo over 48 hours.
• The primary endpoint was the time-weighted sum of pain intensity difference (SPID48).

Main Results:

• High-dose VX-548 significantly reduced acute pain compared to placebo in both abdominoplasty and bunionectomy trials.
• Lower doses of VX-548 did not demonstrate significant pain reduction versus placebo.
• Common adverse events included headache and constipation, generally mild to moderate in severity.

Conclusions:

• High-dose VX-548 demonstrates efficacy in controlling acute postoperative pain.
• The analgesic effect appears dose-dependent, with lower doses being less effective.
• VX-548 presents a potential new option for acute pain management with a manageable safety profile.